These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 1009225)
1. A generalization of the probit and logit methods for dose response curves. Prentice RL Biometrics; 1976 Dec; 32(4):761-8. PubMed ID: 1009225 [TBL] [Abstract][Full Text] [Related]
2. Threshold dose-response models in toxicology. Cox C Biometrics; 1987 Sep; 43(3):511-23. PubMed ID: 3663815 [TBL] [Abstract][Full Text] [Related]
3. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models. Vølund A Biometrics; 1978 Sep; 34(3):357-65. PubMed ID: 719119 [TBL] [Abstract][Full Text] [Related]
4. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. Gardner SN Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708 [TBL] [Abstract][Full Text] [Related]
8. A general noninteractive multiple toxicity model including probit, logit, and Weibull transformations. Christensen ER; Chen CY Biometrics; 1985 Sep; 41(3):711-25. PubMed ID: 4074820 [TBL] [Abstract][Full Text] [Related]
9. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230 [TBL] [Abstract][Full Text] [Related]
10. Mixture models for continuous data in dose-response studies when some animals are unaffected by treatment. Boos DD; Brownie C Biometrics; 1991 Dec; 47(4):1489-504. PubMed ID: 1786327 [TBL] [Abstract][Full Text] [Related]
11. Smooth centile curves for skew and kurtotic data modelled using the Box-Cox power exponential distribution. Rigby RA; Stasinopoulos DM Stat Med; 2004 Oct; 23(19):3053-76. PubMed ID: 15351960 [TBL] [Abstract][Full Text] [Related]
12. Trimmed logit method for estimating the ED50 in quantal bioassay. Sanathanan LP; Gade ET; Shipkowitz NL Biometrics; 1987 Dec; 43(4):825-32. PubMed ID: 3427167 [TBL] [Abstract][Full Text] [Related]
13. Bayesian design for dose-response curves with penalized risk. Sun D; Tsutakawa RK Biometrics; 1997 Dec; 53(4):1262-73. PubMed ID: 9423248 [TBL] [Abstract][Full Text] [Related]
14. Incorporating additional biological phenomena into two-stage cancer models. Sielken RL; Bretzlaff RS; Stevenson DE Prog Clin Biol Res; 1994; 387():237-60. PubMed ID: 7972250 [TBL] [Abstract][Full Text] [Related]
15. Robustness of choice of number of doses for maximum likelihood estimation of the ED(50) in bioassay. Huang Y Stat Med; 2002 Aug; 21(15):2215-23. PubMed ID: 12210634 [TBL] [Abstract][Full Text] [Related]
17. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data. Zhu Y; Wang T; Jelsovsky JZ Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711 [TBL] [Abstract][Full Text] [Related]
18. Dose-response models with covariates. Wijesinha MC; Piantadosi S Biometrics; 1995 Sep; 51(3):977-87. PubMed ID: 7548713 [TBL] [Abstract][Full Text] [Related]
19. Bayesian nonparametric estimation of continuous monotone functions with applications to dose-response analysis. Bornkamp B; Ickstadt K Biometrics; 2009 Mar; 65(1):198-205. PubMed ID: 18510655 [TBL] [Abstract][Full Text] [Related]
20. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Gaylor DW Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]